Question 1

Am I eligible for this trial based on my cancer type and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 clinical trial (NCT06003231). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of disitamab vedotin?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 clinical trial (NCT06003231). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 clinical trial (NCT06003231). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like, and how often will I need to come in for visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 clinical trial (NCT06003231). Contact the study team or your healthcare provider for specific answers.

Question 5

What kind of monitoring will be done during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 clinical trial (NCT06003231). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 clinical trial (NCT06003231). Contact the study team or your healthcare provider for specific answers.

What this study is about